Balance Sheet
Cash Flow Statement
AmortizationAmortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Cash from Investing Activities (2023 - 2025)

Historic Cash from Investing Activities for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $3.7 million.

  • BioLineRx's Cash from Investing Activities fell 6390.17% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 23539.94%. This contributed to the annual value of $29.4 million for FY2024, which is 193421.05% up from last year.
  • BioLineRx's Cash from Investing Activities amounted to $3.7 million in Q3 2025, which was down 6390.17% from -$3.7 million recorded in Q2 2025.
  • In the past 5 years, BioLineRx's Cash from Investing Activities registered a high of $16.7 million during Q1 2024, and its lowest value of -$20.4 million during Q4 2023.
  • For the 3-year period, BioLineRx's Cash from Investing Activities averaged around $2.1 million, with its median value being $4.1 million (2023).
  • Within the past 5 years, the most significant YoY rise in BioLineRx's Cash from Investing Activities was 15470.46% (2024), while the steepest drop was 17788.29% (2024).
  • Quarter analysis of 3 years shows BioLineRx's Cash from Investing Activities stood at -$20.4 million in 2023, then surged by 154.7% to $11.2 million in 2024, then tumbled by 67.08% to $3.7 million in 2025.
  • Its Cash from Investing Activities stands at $3.7 million for Q3 2025, versus -$3.7 million for Q2 2025 and -$8.2 million for Q1 2025.